{
    "id": 50873,
    "name": "follicular lymphoma",
    "source": "DOID",
    "definition": "A B-cell lymphoma that is characterized as an indolent non-Hodgkin's lymphoma and has_material_basis_in follicle center B-cells (centrocytes and centroblasts). [url:http\\://en.wikipedia.org/wiki/Follicular_lymphoma, url:http\\://www.cancer.gov/dictionary?CdrID=428287]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050873",
    "evidence": [
        {
            "id": 4284,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ISIS-STAT3rx (AZD9150) treatment resulted in stable disease in 1 of 2 follicular lymphma patients (PMID: 26582900).",
            "molecularProfile": {
                "id": 17606,
                "profileName": "STAT3 wild-type"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4478,
                    "pubMedId": 26582900,
                    "title": "AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26582900"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4904,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Abexinostat treatment reduced tumor size in 86% (12/14) of follicular lymphoma patients with an observed response rate of 64.3% (9/14) and median progression-free survival of 20.5 months (PMID: 26482040).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1081,
                "therapyName": "Abexinostat",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4787,
                    "pubMedId": 26482040,
                    "title": "A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26482040"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11956,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, Aliqopa (copanlisib) treatment in patients with follicular lymphoma resulted in an objective tumor response rate of 58.7% (61/104) including 14.4% (15/61) patients experiencing a complete response and 44.2% (46/61) patients experiencing a partial response, stable disease in 33.7% (35/104) of patients, and a duration of response of 370 days (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 7535-7535; NCT01660451).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9933,
                    "pubMedId": null,
                    "title": "Copanlisib in patients with relapsed or refractory follicular lymphoma.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7535"
                },
                {
                    "id": 15652,
                    "pubMedId": null,
                    "title": "Aliqopa (copanlisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209936"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5126,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Aliqopa (copanlisib) treatment resulted in complete response in 20% (2/10), partial response in 20% (2/10) and stable disease in 60% (6/10) of patients with follicular lymphoma (PMID: 24852792).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4879,
                    "pubMedId": 24852792,
                    "title": "Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24852792"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5175,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, high-dose TGR-1202 in combination with Ublituximab resulted in complete response in 17% (1/6) and partial response in 33% (2/6) of patients with follicular lymphoma (J Clin Oncol 33, 2015 (suppl; abstr 8548)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2319,
                "therapyName": "Ublituximab + Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4899,
                    "pubMedId": null,
                    "title": "Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL.",
                    "url": "http://meetinglibrary.asco.org/content/152562-156"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6889,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Velcade (Bortezomib) to Bendamustine and Rituxan (rituximab) combination therapy resulted in improved complete response (74%, 63/85) compared to without Velcade (Bortezomib) (58%, 80/137) in high risk follicular lymphoma patients (J Clin Oncol 34, 2016 (suppl; abstr 7507)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4291,
                "therapyName": "Bendamustine + Bortezomib + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5951,
                    "pubMedId": null,
                    "title": "Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408).",
                    "url": "http://abstracts.asco.org/176/AbstView_176_163059.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6952,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) treatment in non-Hodgkin lymphoma (NHL) patients carrying wild-type EZH2 or an EZH2 Y646H mutation resulted in an objective response rate of 60% (3/5) among patients with follicular lymphoma (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).",
            "molecularProfile": {
                "id": 24158,
                "profileName": "EZH2 positive"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5984,
                    "pubMedId": null,
                    "title": "Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients",
                    "url": "http://www.bloodjournal.org/content/126/23/473?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8306,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, Ocaratuzumab (AME-133v) demonstrated safety and some preliminary activity in patients with follicular lymphoma, including those with the Fc-gamma-RIIIa genotype (PMID: 22223529).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4687,
                "therapyName": "Ocaratuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6594,
                    "pubMedId": 22223529,
                    "title": "Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc\u03b3RIIIa-genotyped patients with previously treated follicular lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22223529"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8358,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with CPI-0610 resulted in a partial response in one patient with follicular lymphoma (Blood 2015 126:1491).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2033,
                "therapyName": "CPI-0610",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6630,
                    "pubMedId": null,
                    "title": "BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study",
                    "url": "http://www.bloodjournal.org/content/126/23/1491"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9773,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, the combination of Gazyva (obinutuzumab) plus Treanda (bendamustine) resulted in a greater progression free survival (29.2 mo vs 14.0 mo) than Treanda (bendamustine) alone in patients with follicular lymphoma (PMID: 27345636).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5225,
                "therapyName": "Bendamustine + Obinutuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7595,
                    "pubMedId": 27345636,
                    "title": "Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27345636"
                },
                {
                    "id": 15648,
                    "pubMedId": null,
                    "title": "Gazyva (obinutuzumab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125486"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11300,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Rituxan (rituximab) treatment in patients with follicular lymphoma resulted in an overall survival of 84.9% in patients receiving the drug intravenously and 84.4% in patients receiving the drug subcutaneously (PMID: 28476440).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9223,
                    "pubMedId": 28476440,
                    "title": "Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28476440"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Imbruvica (ibrutinib) and Venclexta (venetoclax) resulted in a synergistic effect, demonstrating growth suppression in follicular lymphoma cell lines in culture (PMID: 28428442).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9292,
                    "pubMedId": 28428442,
                    "title": "Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28428442"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11613,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with follicular lymphoma treated with a combination of Veliparib (ABT-888) and Bendamustine demonstrated a complete response (PMID: 28314788; NCT01326702).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6076,
                "therapyName": "Bendamustine + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9669,
                    "pubMedId": 28314788,
                    "title": "The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28314788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11614,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, five patients with follicular lymphoma treated with a combination of Bendamustine, Rituxan (rituximab), and Veliparib (ABT-888) demonstrated a complete response (PMID: 28314788; NCT01326702).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6077,
                "therapyName": "Bendamustine + Rituximab + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9669,
                    "pubMedId": 28314788,
                    "title": "The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28314788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12118,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Umbralisib (TGR-1202) treatment resulted in complete response in 12% (2/17) and partial response in 41% (7/17) of patients with follicular lymphoma (PMID: 29475723; NCT01767766).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2022,
                "therapyName": "Umbralisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11343,
                    "pubMedId": 29475723,
                    "title": "Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29475723"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12848,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical trial that supported FDA approval, treatment with Rituxan (rituximab) resulted in a response rate of 48% in patients (n=166) with relapsed low-grade or follicular, MS4A1 (CD20)-positive, B-cell non-Hodgkin lymphoma (PMID: 9704735).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10804,
                    "pubMedId": 9704735,
                    "title": "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9704735"
                },
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17568,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, Rituxan (rituximab) treatment resulted in an overall response rate of 57% (21/37, 5 complete response, 16 partial response) in patients with relapsed or refractory, low-grade or follicular, MS4A1 (CD20)-positive, B-cell non-Hodgkin lymphoma (PMID: 10442187).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15635,
                    "pubMedId": 10442187,
                    "title": "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10442187"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17573,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (PRIMA) that supported FDA approval, Rituxan (rituximab) maintenance therapy improved progression-free survival rate (74.9% vs 57.6%, HR=0.55, p<0.0001) compared to observation only in patients with previously untreated follicular lymphoma who achieved complete or partial response to first-line chemotherapy (PMID: 21176949; NCT00140582).",
            "molecularProfile": {
                "id": 15367,
                "profileName": "MS4A1 positive"
            },
            "therapy": {
                "id": 897,
                "therapyName": "Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15611,
                    "pubMedId": null,
                    "title": "Rituxan (rituximab) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705"
                },
                {
                    "id": 15636,
                    "pubMedId": 21176949,
                    "title": "Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21176949"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14314,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Buparlisib (BKM120) and Imbruvica (ibrutinib) combination treatment resulted in a best overall response rate of 20% (1/5, 1 complete response) in patients with relapsed/refractory follicular lymphoma (J Clin Oncol 36, 2018 (suppl; abstr 7520); NCT02756247).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3630,
                "therapyName": "Buparlisib + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11582,
                    "pubMedId": null,
                    "title": "Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.",
                    "url": "http://abstracts.asco.org/214/AbstView_214_229221.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16083,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib study, combined Hu5F9-G4 and Rituxan (rituximab) therapy demonstrated safety and efficacy, resulting in an objective response rate of 71% (5/7, 3 complete and 2 partial responses) in patients with follicular lymphoma, and a median duration of response longer than 6 months (PMID: 30380386).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4955,
                "therapyName": "Hu5F9-G4 + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14206,
                    "pubMedId": 30380386,
                    "title": "CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30380386"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16520,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Parsaclisib (INCB050465) treatment demonstrated tolerability and preliminary activity in patients with refractory B-cell malignancies, and resulted in an overall response rate of 71% (10/14), complete response/complete metabolic response rate of 21% (3/14), and median duration of response was not reached patients with follicular lymphoma (PMID: 30803990; NCT02018861).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3088,
                "therapyName": "Parsaclisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14606,
                    "pubMedId": 30803990,
                    "title": "Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30803990"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16693,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, Zydelig (idelalisib) treatment resulted in an overall response rate of 54% (39/72, 6 complete response, 33 partial response) in patients with relapsed follicular lymphoma (PMID: 24450858; NCT01282424).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1023,
                "therapyName": "Idelalisib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14717,
                    "pubMedId": 24450858,
                    "title": "PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24450858"
                },
                {
                    "id": 15610,
                    "pubMedId": null,
                    "title": "Zydelig (idelalisib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205858"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16709,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AGS67E inhibited growth of a CD37-positive follicular lymphoma cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25934707).",
            "molecularProfile": {
                "id": 30535,
                "profileName": "CD37 positive"
            },
            "therapy": {
                "id": 8154,
                "therapyName": "AGS67E",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14736,
                    "pubMedId": 25934707,
                    "title": "AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25934707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17122,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (AUGMENT) that supported FDA approval, Revlimid (lenalidomide) in combination with Rituxan (rituximab) resulted in significantly improved progression-free survival (39.4 vs 14.1 months, HR=0.46, p<0.001) compared to placebo and Rituxan (rituximab) in patients with relapsed and/or refractory follicular or marginal zone lymphoma (PMID: 30897038; NCT01938001).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8309,
                "therapyName": "Lenalidomide + Rituximab",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15200,
                    "pubMedId": 30897038,
                    "title": "AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30897038"
                },
                {
                    "id": 15666,
                    "pubMedId": null,
                    "title": "Revlimid (lenalidomide) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18736,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APG-2575 and Imbruvica (ibrutinib) combination therapy exhibited synergistic antitumor activity in a cell-line xenograft model of follicular lymphoma (Cancer Res July 1 2019 (79) (13 Supplement) 2058).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8826,
                "therapyName": "APG-2575 + Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16405,
                    "pubMedId": null,
                    "title": "BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma",
                    "url": "https://cancerres.aacrjournals.org/content/79/13_Supplement/2058"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19098,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BCL2 rearrangement aids in the diagnosis of follicular lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15361,
                "profileName": "BCL2 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19100,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BCL6 rearrangement aids in the diagnosis of pediatric-type follicular lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15362,
                "profileName": "BCL6 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19102,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "IRF4 rearrangement aids in the diagnosis of follicular lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 31553,
                "profileName": "IRF4 rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19560,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tazemetostat (EPZ-6438) treatment resulted in an objective response in 71% (20/28, 3 complete response, 17 partial response) and stable disease in 29% (8/28) of patients with relapsed or refractory follicular lymphoma harboring EZH2 mutations, while only resulted in object response rate in 33% (18/54, 3 complete response, 15 partial response) and stable disease in 31% (16/54) of patients with EZH2 wild-type disease (PMID: 29980507).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17175,
                    "pubMedId": 29980507,
                    "title": "Positive Results for Tazemetostat in Follicular Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29980507"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19562,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) demonstrated safety and preliminary efficacy, resulted in 2 complete responses and 1 partial response in patients with relapsed or refractory follicular lymphoma (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20200,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "TNFRSF14 mutations aid in the diagnosis of follicular lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 34920,
                "profileName": "TNFRSF14 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20201,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "STAT6 mutations aid in the diagnosis of follicular lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 22435,
                "profileName": "STAT6 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20611,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, follicular lymphoma patients tolerated MOR208 treatment, and achieved an overall response rate of 29% (10/34, 3 complete and 7 partial response) with 4 patients responding over 12 months, a disease control rate of 76% (26/34), progression-free survival of 8.8 months at a median follow-up of 21 months, and a median duration of response was not reached (PMID: 29444231; NCT01685008).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5783,
                "therapyName": "MOR208",
                "synonyms": null
            },
            "indication": {
                "id": 50873,
                "name": "follicular lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17962,
                    "pubMedId": 29444231,
                    "title": "Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29444231"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00577278",
            "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 767,
                    "therapyName": "Ibritumomab tiuxetan",
                    "synonyms": null
                },
                {
                    "id": 2238,
                    "therapyName": "Methotrexate + Sirolimus + Tacrolimus",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2237,
                    "therapyName": "Fludarabine + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00602693",
            "title": "T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 2311,
                    "therapyName": "Allopurinol + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT00671112",
            "title": "Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2234,
                    "therapyName": "Bortezomib + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01193842",
            "title": "Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1077,
                    "therapyName": "Vorinostat",
                    "synonyms": null
                },
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01216683",
            "title": "Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 688,
                    "therapyName": "Bortezomib",
                    "synonyms": null
                },
                {
                    "id": 1164,
                    "therapyName": "Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01286272",
            "title": "Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3909,
                    "therapyName": "Bendamustine + Ofatumumab",
                    "synonyms": null
                },
                {
                    "id": 3910,
                    "therapyName": "Bendamustine + Bortezomib + Ofatumumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01307267",
            "title": "A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6111,
                    "therapyName": "Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 5086,
                    "therapyName": "Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01691898",
            "title": "A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS)",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4415,
                    "therapyName": "Obinutuzumab + Pinatuzumab Vedotin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4416,
                    "therapyName": "Pinatuzumab Vedotin + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4417,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01719250",
            "title": "Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 680,
                    "therapyName": "Buparlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01732913",
            "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01732926",
            "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
            "phase": "Phase III",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01796171",
            "title": "A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7920,
                    "therapyName": "Lilotomab",
                    "synonyms": null
                },
                {
                    "id": 7393,
                    "therapyName": "Betalutin",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01804686",
            "title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)",
            "phase": "Phase III",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01811368",
            "title": "Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9105,
                    "therapyName": "anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2272,
                    "therapyName": "Cyclosporine + Mycophenolate mofetil",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01897012",
            "title": "Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1075,
                    "therapyName": "Romidepsin",
                    "synonyms": null
                },
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01953692",
            "title": "A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01955499",
            "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3580,
                    "therapyName": "Ibrutinib + Lenalidomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01974440",
            "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                }
            ]
        },
        {
            "nctId": "NCT01976585",
            "title": "In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4337,
                    "therapyName": "CDX-301 + Poly ICLC",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01994382",
            "title": "Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2531,
                    "therapyName": "Cerdulatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02038946",
            "title": "Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02049541",
            "title": "Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2502,
                    "therapyName": "Buparlisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02082977",
            "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 2925,
                    "therapyName": "GSK126",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02106091",
            "title": "Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7390,
                    "therapyName": "AFM11",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02187861",
            "title": "A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 3637,
                    "therapyName": "Bendamustine + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 3937,
                    "therapyName": "Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02194751",
            "title": "Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9754,
                    "therapyName": "Oncoquest-L vaccine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02208037",
            "title": "Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02220842",
            "title": "A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02254772",
            "title": "TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3848,
                    "therapyName": "Ipilimumab + SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02257567",
            "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4226,
                    "therapyName": "Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02266147",
            "title": "Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3084,
                    "therapyName": "SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02282358",
            "title": "Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3002,
                    "therapyName": "Mocetinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02320292",
            "title": "Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9616,
                    "therapyName": "Ibritumomab tiuxetan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02339922",
            "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6730,
                    "therapyName": "Ixazomib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02343536",
            "title": "A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2488,
                    "therapyName": "Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "R-CHOP"
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02348216",
            "title": "A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4829,
                    "therapyName": "KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02367040",
            "title": "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02369016",
            "title": "Phase III Copanlisib in Rituximab-refractory iNHL",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02376699",
            "title": "Safety Study of SEA-CD40 in Cancer Patients",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5781,
                    "therapyName": "Pembrolizumab + SEA-CD40",
                    "synonyms": null
                },
                {
                    "id": 5780,
                    "therapyName": "SEA-CD40",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02381080",
            "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3793,
                    "therapyName": "Erythromycin + Ibrutinib + Voriconazole",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02384954",
            "title": "ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3936,
                    "therapyName": "ALT-803 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02401048",
            "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2573,
                    "therapyName": "Durvalumab + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02440685",
            "title": "A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7391,
                    "therapyName": "ASN002",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446457",
            "title": "Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3279,
                    "therapyName": "Pembrolizumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454270",
            "title": "A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4166,
                    "therapyName": "JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02471911",
            "title": "KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 3360,
                    "therapyName": "Carboplatin + Etoposide + Ifosfamide + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02501473",
            "title": "Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3577,
                    "therapyName": "GLA-SE + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02532192",
            "title": "A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 1390,
                    "therapyName": "Dexamethasone",
                    "synonyms": null
                },
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1689,
                    "therapyName": "Fluconazole",
                    "synonyms": null
                },
                {
                    "id": 1078,
                    "therapyName": "Belinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02532257",
            "title": "Study of Ibrutinib in Combination With Rituximab and Lenalidomide",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1610,
                    "therapyName": "Ibrutinib + Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02536300",
            "title": "Dose Optimization Study of Idelalisib in Follicular Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564744",
            "title": "Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6931,
                    "therapyName": "IMGN529 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02576275",
            "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
            "phase": "Phase III",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 1024,
                    "therapyName": "Duvelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02596971",
            "title": "Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1975,
                    "therapyName": "Atezolizumab + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 3266,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Vincristine",
                    "synonyms": "CHOP"
                },
                {
                    "id": 1231,
                    "therapyName": "Bendamustine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02600897",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4394,
                    "therapyName": "Lenalidomide + Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02603445",
            "title": "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 6461,
                    "therapyName": "BCL201 + Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02605694",
            "title": "Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3389,
                    "therapyName": "Duvelisib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT02611323",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4227,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02624986",
            "title": "A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 4393,
                    "therapyName": "Idasanutlin + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02626455",
            "title": "Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1631,
                    "therapyName": "Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                },
                {
                    "id": 3388,
                    "therapyName": "Aldoxorubicin + Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                },
                {
                    "id": 2323,
                    "therapyName": "Bendamustine + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631044",
            "title": "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631577",
            "title": "A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3387,
                    "therapyName": "Atezolizumab + Lenalidomide + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02650999",
            "title": "Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02700022",
            "title": "A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 626,
                    "therapyName": "Alisertib",
                    "synonyms": null
                },
                {
                    "id": 3395,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02722668",
            "title": "UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2281,
                    "therapyName": "Cyclophosphamide + Fludarabine + Mycophenolate mofetil",
                    "synonyms": null
                },
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                },
                {
                    "id": 1844,
                    "therapyName": "anti-thymocyte globulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02729896",
            "title": "A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8255,
                    "therapyName": "Obinutuzumab + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 4362,
                    "therapyName": "Atezolizumab + Obinutuzumab + Polatuzumab vedotin-piiq",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02743546",
            "title": "Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4167,
                    "therapyName": "Ibrutinib + JNJ-64052781",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02747043",
            "title": "Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)",
            "phase": "Phase III",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7365,
                    "therapyName": "ABP 798",
                    "synonyms": null
                },
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02756247",
            "title": "A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3630,
                    "therapyName": "Buparlisib + Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02776813",
            "title": "Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 7267,
                    "therapyName": "ACTR087 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02797470",
            "title": "Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9777,
                    "therapyName": "Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02869633",
            "title": "Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02900716",
            "title": "Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7345,
                    "therapyName": "DTRMWXHS-12 + Everolimus + Pomalidomide",
                    "synonyms": null
                },
                {
                    "id": 7344,
                    "therapyName": "DTRMWXHS-12",
                    "synonyms": null
                },
                {
                    "id": 7347,
                    "therapyName": "DTRMWXHS-12 + Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02914938",
            "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6745,
                    "therapyName": "ME-401",
                    "synonyms": null
                },
                {
                    "id": 6746,
                    "therapyName": "ME-401 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02927964",
            "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4828,
                    "therapyName": "Ibrutinib + Radiotherapy + SD-101",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02931110",
            "title": "Study of IV CBL0137 in Previously Treated Hematological Subjects",
            "phase": "Phase I",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 3940,
                    "therapyName": "CBL0137",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02947347",
            "title": "Study of Ibrutinib and Rituximab in Treatment Na\u00efve Follicular Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                },
                {
                    "id": 3280,
                    "therapyName": "Ibrutinib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02950220",
            "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4917,
                    "therapyName": "Ibrutinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02953509",
            "title": "Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4955,
                    "therapyName": "Hu5F9-G4 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02956382",
            "title": "Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3392,
                    "therapyName": "Ibrutinib + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02966730",
            "title": "Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 768,
                    "therapyName": "Ibrutinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02992522",
            "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5133,
                    "therapyName": "Lenalidomide + Obinutuzumab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03010358",
            "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8065,
                    "therapyName": "Entospletinib + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03015896",
            "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5239,
                    "therapyName": "Lenalidomide + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03019640",
            "title": "Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6934,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03039114",
            "title": "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6260,
                    "therapyName": "Bendamustine + Obinutuzumab + Parsaclisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03105336",
            "title": "A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4829,
                    "therapyName": "KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03113422",
            "title": "Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 3636,
                    "therapyName": "Obinutuzumab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 3638,
                    "therapyName": "Bendamustine + Obinutuzumab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03121677",
            "title": "Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5592,
                    "therapyName": "Nivolumab + Poly ICLC + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03126019",
            "title": "An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3088,
                    "therapyName": "Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03133221",
            "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1023,
                    "therapyName": "Idelalisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03135262",
            "title": "A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5646,
                    "therapyName": "Idasanutlin + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 5644,
                    "therapyName": "Idasanutlin + Obinutuzumab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 5645,
                    "therapyName": "Idasanutlin + Obinutuzumab + Rituximab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03147885",
            "title": "Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03150329",
            "title": "Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3077,
                    "therapyName": "Pembrolizumab + Vorinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03153462",
            "title": "Axicabtagene Ciloleucel Expanded Access Study",
            "phase": "Expanded access",
            "recruitment": "Available",
            "therapies": [
                {
                    "id": 5098,
                    "therapyName": "Cyclophosphamide + Fludarabine + KTE-C19",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03156114",
            "title": "This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5692,
                    "therapyName": "BI 754091",
                    "synonyms": null
                },
                {
                    "id": 5690,
                    "therapyName": "BI 754111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03178201",
            "title": "TGR1202 in Relapsed and Refractory Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2022,
                    "therapyName": "Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03179930",
            "title": "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3354,
                    "therapyName": "Entinostat + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03189836",
            "title": "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7386,
                    "therapyName": "ACTR707 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03198026",
            "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3476,
                    "therapyName": "Ibrutinib + Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03269669",
            "title": "Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6257,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine",
                    "synonyms": "Obinutuzumab + CHOP"
                },
                {
                    "id": 6302,
                    "therapyName": "Lenalidomide + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 6301,
                    "therapyName": "Obinutuzumab + Umbralisib",
                    "synonyms": null
                },
                {
                    "id": 2188,
                    "therapyName": "Prednisone",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03277729",
            "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9487,
                    "therapyName": "CD20 CAR T-cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03297424",
            "title": "A Study of PLX2853 in Advanced Malignancies.",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6324,
                    "therapyName": "PLX2853",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03321643",
            "title": "Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6379,
                    "therapyName": "Atezolizumab + Gemcitabine + Oxaliplatin + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 6380,
                    "therapyName": "Atezolizumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03332017",
            "title": "A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4682,
                    "therapyName": "Obinutuzumab + Zanubrutinib",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357627",
            "title": "A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 6911,
                    "therapyName": "TAK-659 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03361852",
            "title": "A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9113,
                    "therapyName": "NeoVax + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03379493",
            "title": "Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT03401853",
            "title": "Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3279,
                    "therapyName": "Pembrolizumab + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424122",
            "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7351,
                    "therapyName": "Ibrutinib + Parsaclisib",
                    "synonyms": null
                },
                {
                    "id": 7350,
                    "therapyName": "Bendamustine + Parsaclisib + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7349,
                    "therapyName": "Parsaclisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03424603",
            "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7413,
                    "therapyName": "STRO-001",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03460977",
            "title": "PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6785,
                    "therapyName": "PF-06821497",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03465891",
            "title": "Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1201,
                    "therapyName": "Atezolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03479268",
            "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7712,
                    "therapyName": "Ibrutinib + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03483103",
            "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5980,
                    "therapyName": "JCAR017",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03498612",
            "title": "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03547115",
            "title": "A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 842,
                    "therapyName": "Voruciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03568461",
            "title": "Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03571568",
            "title": "A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9353,
                    "therapyName": "BI-1206 + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03579927",
            "title": "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 1632,
                    "therapyName": "Filgrastim",
                    "synonyms": null
                },
                {
                    "id": 6213,
                    "therapyName": "iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                },
                {
                    "id": 7797,
                    "therapyName": "Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03585725",
            "title": "A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3167,
                    "therapyName": "Ribavirin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03600441",
            "title": "Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1081,
                    "therapyName": "Abexinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03610724",
            "title": "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients (BIANCA)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5981,
                    "therapyName": "Tisagenlecleucel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03636503",
            "title": "RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5087,
                    "therapyName": "Avelumab + Rituximab + Utomilumab",
                    "synonyms": null
                },
                {
                    "id": 7849,
                    "therapyName": "Avelumab + PF-04518600 + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 7848,
                    "therapyName": "PF-04518600 + Rituximab + Utomilumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03671018",
            "title": "A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                },
                {
                    "id": 2488,
                    "therapyName": "Cyclophosphamide + Prednisone + Rituximab + Vincristine",
                    "synonyms": "R-CHOP"
                },
                {
                    "id": 7624,
                    "therapyName": "Bendamustine + Polatuzumab vedotin-piiq + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 5225,
                    "therapyName": "Bendamustine + Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 7623,
                    "therapyName": "BTCT4465A + Polatuzumab vedotin-piiq",
                    "synonyms": null
                },
                {
                    "id": 6304,
                    "therapyName": "BTCT4465A",
                    "synonyms": null
                },
                {
                    "id": 1646,
                    "therapyName": "Obinutuzumab",
                    "synonyms": null
                },
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03682796",
            "title": "Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8156,
                    "therapyName": "TRPH-222",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03685344",
            "title": "Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7646,
                    "therapyName": "Durvalumab + Loncastuximab tesirine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03711578",
            "title": "Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2020,
                    "therapyName": "RP6530",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03740529",
            "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9507,
                    "therapyName": "Cyclophosphamide + Doxorubicin + LOXO-305 + Prednisone + Rituximab + Vincristine",
                    "synonyms": "LOXO-305 + R-CHOP"
                },
                {
                    "id": 9506,
                    "therapyName": "LOXO-305 + Rituximab + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9505,
                    "therapyName": "LOXO-305 + Venetoclax",
                    "synonyms": null
                },
                {
                    "id": 9504,
                    "therapyName": "LOXO-305",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03758989",
            "title": "A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2195,
                    "therapyName": "Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine",
                    "synonyms": "Rituximab + CHOP|RCHOP"
                }
            ]
        },
        {
            "nctId": "NCT03768505",
            "title": "Study of ME-401 in Subjects With Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6745,
                    "therapyName": "ME-401",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03779113",
            "title": "An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5279,
                    "therapyName": "HMPL-523",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03786926",
            "title": "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3669,
                    "therapyName": "HMPL-689",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03789240",
            "title": "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7697,
                    "therapyName": "Copanlisib + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03828448",
            "title": "Study to Assess Umbralisib Plus Ublituximab in Patients With Treatment Naive Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2319,
                    "therapyName": "Ublituximab + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03884998",
            "title": "Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6899,
                    "therapyName": "Copanlisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03888105",
            "title": "Assess the Anti-Tumor Activity and Safety of REGN1979 in Patients With Relapsed or Refractory Follicular Lymphoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6151,
                    "therapyName": "REGN1979",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03892044",
            "title": "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8116,
                    "therapyName": "Duvelisib + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03919175",
            "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8190,
                    "therapyName": "Rituximab + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03920631",
            "title": "Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03976102",
            "title": "Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera in LTB Follicular Lymphoma (FLINTER) (FLINTER)",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 897,
                    "therapyName": "Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9117,
                    "therapyName": "DRL_RI",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03980171",
            "title": "Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Na\u00efve Follicular Lymphoma (LEVERAGE)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5133,
                    "therapyName": "Lenalidomide + Obinutuzumab + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04007029",
            "title": "Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5647,
                    "therapyName": "Tocilizumab",
                    "synonyms": null
                },
                {
                    "id": 8530,
                    "therapyName": "Anti-CD19/CD20 CAR T cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04038359",
            "title": "A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1024,
                    "therapyName": "Duvelisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04074330",
            "title": "A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9146,
                    "therapyName": "Rituximab + TAK-981",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04082936",
            "title": "A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9443,
                    "therapyName": "IGM-2323",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04156828",
            "title": "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8925,
                    "therapyName": "Carboplatin + Copanlisib + Dexamethasone + Gemcitabine + Pegfilgrastim + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04205409",
            "title": "Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04223765",
            "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9229,
                    "therapyName": "Bendamustine + CAR.k.28 cells + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 9230,
                    "therapyName": "CAR.k.28 cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04224493",
            "title": "Study in Subjects With Relapsed/Refractory Follicular Lymphoma",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9246,
                    "therapyName": "Lenalidomide + Rituximab + Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 8309,
                    "therapyName": "Lenalidomide + Rituximab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04231747",
            "title": "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9650,
                    "therapyName": "CC-97540",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04283097",
            "title": "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9479,
                    "therapyName": "KPG-818",
                    "synonyms": null
                }
            ]
        }
    ]
}